Shares of Amgen Inc. AMGN inched 0.08% higher to $278.32 Tuesday, on what proved to be an all-around mixed trading session ...

Patients with recurrent platinum-sensitive ovarian cancer did just as well with cytoreductive surgery alone as they did with ...

"Importantly, although the most commonly considered osteoporotic fractures (hip, vertebral, forearm, humerus, and pelvis) ...

Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Stocks shrug off a new Trump tariff threat as the president-elect vows sweeping levies on the biggest U.S. trading partners.

Local hospitals, biotech companies and their spinoffs are seeing years of hard work pay off in the laboratory as well as in ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

The donation to Rush’s orthopedic department, the largest ever, creates four new endowed positions and programs.